Naoyuki Kanzaki

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

Masanori Baba, Osamu Nishimura, Naoyuki Kanzaki et al. · Proceedings of the National Academy of Sciences · 1999 · 755 citations · Full text

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

Takahito Hara, Jun‐ichi Miyazaki, Hideo Araki et al. · PubMed · 2003 · 427 citations

Molecular Pharmacology, Androgen Receptor, Urology +12

T140 analogs as CXCR4 antagonists identified as anti‐metastatic agents in the treatment of breast cancer

Hirokazu Tamamura, Akira Hori, Naoyuki Kanzaki et al. · FEBS Letters · 2003 · 281 citations · Full text

Inhibitory Activity, T140 Analogs, Breast Oncology +14

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist

Nobuyuki Negoro, Shinobu Sasaki, Satoshi Mikami et al. · ACS Medicinal Chemistry Letters · 2010 · 246 citations · Full text

Molecular Pharmacology, Pharmaceutical Science, Selective Gpr40 Agonist +12

Discovery of Novel, Potent, and Selective Small-Molecule CCR5 Antagonists as Anti-HIV-1 Agents:  Synthesis and Biological Evaluation of Anilide Derivatives with a Quaternary Ammonium Moiety

Mitsuru Shiraishi, Yoshio Aramaki, Masaki Seto et al. · Journal of Medicinal Chemistry · 2000 · 185 citations · Full text

Lead Compounds, Cho/ccr5 Cells, Lead Identification +19